NCT04595994View on ClinicalTrials.gov

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

May 31, 2026

Conditions
Sarcoma,Soft Tissue
Interventions
DRUG

Selinexor

For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).

Trial Locations (6)

28040

RECRUITING

H. Fundación Jiménez Díaz, Madrid

RECRUITING

Hospital Clínico San Carlos, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

50009

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

08025

ACTIVE_NOT_RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

RECRUITING

HU Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Grupo Espanol de Investigacion en Sarcomas

OTHER